A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASCEND; ASCEND in SPMS
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results assessing long term efficacy of natalizumab in ASCEND extension study, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of post hoc analysis assessing sustained disability improvements over 2 years, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 17 Sep 2016 Post-hoc subgroup analysis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top